Acorda Buys Neurology Drug Developer Civitas Ahead Of IPO
This article was originally published in The Pink Sheet Daily
Executive Summary
Acorda gains an inhalable dry-powder version of levodopa, which it plans to move into a Phase III trial for the treatment of Parkinson’s disease in 2015, in exchange for $525 million in cash.